Results 271 to 280 of about 784,891 (338)

Remnant cholesterol and its variability independent of low density lipoprotein cholesterol predict metabolic dysfunction associated steatotic liver disease. [PDF]

Sci Rep
Sun Y, Miao X, Hu M, Xie X, Liu S, Song Z, Deng J, Xu F, Li M, He Y, Leng S.   +10 more
europepmc   +1 more source

The Low-Density Lipoprotein Receptor-Related Protein-1 Is Essential for Dengue Virus Infection. [PDF]

Viruses
Huerta V, Martin AM, Sarría M, Guirola O, Yero A, Ramos Y, Pupo D, Martin D, Carletti T, González-Lodeiro LG, Marcello A, Chinea G.   +11 more
europepmc   +1 more source

Harnessing Viral Proteases for Cellular and Molecular Engineering

Chemistry–Methods, EarlyView.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui, Tien‐Hung Lan, Yubin Zhou   +2 more
wiley   +1 more source

Effect of Succinylation on Oxidation-Aggregation of Low-Density Lipoprotein and Formation of Off-Flavors in Heated Egg Yolks. [PDF]

Foods
Ren L, Sun C, Lv Y, Kumar L.
europepmc   +1 more source

Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics

Clinical Pharmacology &Therapeutics, EarlyView.
The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou, Rohit Rao, Monica E. Shapiro, Nessy Tania, Cody Herron, Cynthia J. Musante, Jim H. Hughes   +6 more
wiley   +1 more source

Discordance Between Very Low-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol Increases Cardiovascular Disease Risk in a Geographically Defined Cohort. [PDF]

J Am Heart Assoc
Seehusen KE, Remaley AT, Sampson M, Meeusen JW, Larson NB, Decker PA, Killian JM, Takahashi PY, Roger VL, Manemann SM, Lam R, Bielinski SJ.   +11 more
europepmc   +1 more source

Attainment of low-density lipoprotein cholesterol goals in patients undergoing coronary revascularization in the contemporary clinical practice. [PDF]

Indian Heart J
Bansal M, Kasliwal RR, Chandra P, Kapoor R, Chouhan N, Bhan A, Trehan N.   +6 more
europepmc   +1 more source

Annual Banned‐Substance Review 17th Edition—Analytical Approaches in Human Sports Drug Testing 2023/2024

Drug Testing and Analysis, EarlyView.
Scenarios of drug exposure and administration as well as detection assays for drugs and methods of sports doping published between 2023 and 2024 are critically reviewed and evaluated in context with the Prohibited List 2024 as established by the World Anti‐Doping Agency.
Mario  Thevis, Tiia  Kuuranne, Hans  Geyer   +2 more
wiley   +1 more source

A non-linear association of low-density lipoprotein cholesterol with all-cause and cardiovascular mortality among patients with hypertension. [PDF]

Front Cardiovasc Med
Liang G, Zhang W, Gu X, Zhang Q, Liu A, Qing X, Ma J.   +6 more
europepmc   +1 more source